Get started
Amgen Inc.AA

Amgen Inc.

312.38USDR
+0.83+0.27%
As of today at 15:15 GMT
USD
No trades
See on Supercharts
Overview Financials News
Ideas
Discussions Technicals Forecast Seasonals Options Bonds

AMGN trade ideas

Amgen Bull Flag: Just What the Doctor Ordered?Biotechnology stocks surged in the fourth quarter thanks to some takeovers and buyers returning to the health-care sector. Amgen is the biggest of all the biotechs with $144 billion of market cap. It's also one of the few big names that's broken out to new highs. (Along with Vertex .) AMGN's been climbing a wall of worry about competition since the summer. The flurry of good news began in June when its AMG 510 cancer compound successfully shrank lung tumors. Then, earnings beat in both July and October as its new biosimilar franchise surprised the naysayers. Now's the first real pullback since breaking out. AMGN's bullish flag may create potential for a continuation move higher, with Friday's low of $236.24 as a level for risk management. The next earnings report is estimated for Jan. 28.
NLong
by TradeStation
$AMGN Technical and fundamental Breakout in AmgenEntry level $216 = Target price $237 = Stop loss $209 Bullish technical setup, Fundamentally bullish with superb earnings and the announcement that they have taken a stake in BieGene, the wider the open the vault the better, start spending that cash hoard. P/E ratio 16.36 Yield, 2.75% Company profile Amgen, Inc. is a biotechnology company, which engages in the discovery, development, manufacture and marketing of human therapeutics. Its products include the following brands: Aranesp, BLINCYTO, Corlanor, ENBREL, EPOGEN, IMLYGIC, KYPROLIS, Neulasta, NEUPOGEN, Nplate, Parsabiv, Prolia, Repatha, Sensipar, Vectibix, and XGEVA. The company was founded by William K. Bowes, Jr., Franklin Pitcher Johnson, Jr., George B. Rathmann and Joseph Rubinfeld on April 8, 1980 and is headquartered in Thousand Oaks, CA.
NLong
by Bullishcharts
1
AMGEN Inc AMGN stock looks attractive after a strong rallyAMGEN Inc AMGN american stock looks attractive after a strong rally, waiting for a pullback to weekly demand imbalance around $178 to buy the underlying stock. We don't need any fundamental analysis on a stock to take a trading decision but if you are interested, Amgen AMGN has been a laggard. Amgen's slump had to do with the stocks slowing growth outlook combined with the ever present headwinds that the healthcare sector faces heading into an election year.However, Amgen could address its growth slump. That's exactly what management did in August, causing the stock's price to spike. Yet, in the past five weeks Amgen shares have cooled off, giving investors who were previously experiencing fear of missing out the trade, the chance to get into the stock at a discount to recent highs. Where is the place where those investors can plan to buy AMGEN again? Well, if you look at the attached weekly chart technical analysis, the whole movement started at $178 creating a very strong weekly demand level, that's where we can buy AMGEN inc again.
NLong
by AlfonsoMoreno
AMGN attempting trend line breakout ahead of earningsAmgen is attempting a breakout above its one-month downward trend line this morning. I will wait to enter until I see a change in volume. Currently there's bearish divergence on the volume profile, which suggests that this may correct downward before confirming the breakout. Amgen reports earnings tomorrow, and has a positive earnings surprise prediction from Zacks. Amgen has beaten analyst estimates 7 of 8 quarters in the last 2 years. The company's recent price weakness and great valuation (15.8% below the average analyst price target) makes it a good candidate for a pop on an earnings beat.
NLong
by ChristopherCarrollSmith
Daily AMGN forecast timing analysis by Supply-Demand strength21-Jun Investing strategies by pretiming Investing position about Supply-Demand(S&D) strength: In Rising section of high profit & low risk Supply-Demand(S&D) strength Trend Analysis: In the midst of an upward trend of strong upward momentum price flow marked by the temporary falls and strong rises. Today's S&D strength Flow: Supply-Demand strength has changed from a weak buying flow to a strengthening buying flow again. View a Forecast Candlestick Shape Analysis of 10 days in the future: www.pretiming.com (You can easily create a trading plan.) D+1 Candlestick Color forecast: GREEN Candlestick %D+1 Range forecast: 0.8% (HIGH) ~ 0.1% (LOW), 0.4% (CLOSE) %AVG in case of rising: 1.2% (HIGH) ~ -0.6% (LOW), 0.8% (CLOSE) %AVG in case of falling: 0.5% (HIGH) ~ -1.4% (LOW), -0.8% (CLOSE) Price Forecast Timing Criteria: Price forecast timing is analyzed based on pretiming algorithm of Supply-Demand(S&D) strength.
NLong
by pretiming
AMGEN- Overbought, or Cup and handle?RSI is definitely overbought. This COULD lead to a PERFECTLY set up cup and handle right before earnings to pump this up. Earnings is on July 29. More than enough time to fill out the Cup, and form a handle for an explosive move up before earnings. We are at the top BB so it could be a week or 2 before hitting the top to see if a handle forms, if AMGEN goes parabolic, or if this was a suckers rally. This is purely speculation. I do not plan on trading this in the next 72 hours. DYOR.
N
by MichaelMF
$AMGN A big week ahead for Amgen, now it's found a bottom. Amgen will present data from its oncology pipeline at the 55th Annual Meeting of the American Society of Clinical Oncology that begins on May 31. This Could a hugely significant day for NASDAQ:AMGN which is in need of some good news to reassure investors. They stock has been on a terrible run lately but it may now have found a bottom, ready to move higher as the entire sector sell-off has left these companies at very attractive P/E ratios, offering stability and cash generation at a time when tech is in the wars. RECENT DEVELOPMENTS Amgen (NASDAQ:AMGN) has made a cash offer of SEK 1,610 (US$167M) for Copenhagen-based Nuevolution AB, a developer of small molecule therapeutics in inflammation, oncology and immuno-oncology utilizing its drug discovery platform called Chemetics. AVERAGE ANALYSTS PRICE TARGET $206 AVERAGE ANALYSTS RECOMMENDATION OVERWEIGHT 12 BUY 1 OVERWEIGHT 1 2 HOLD P/E RATIO 13.66 COMPANY PROFILE Amgen, Inc. is a biotechnology company, which engages in the discovery, development, manufacture and marketing of human therapeutics. Its products include the following brands: Aranesp, BLINCYTO, Corlanor, ENBREL, EPOGEN, IMLYGIC, KYPROLIS, Neulasta, NEUPOGEN, Nplate, Parsabiv, Prolia, Repatha, Sensipar, Vectibix, and XGEVA.
NLong
by RedHotStocks